Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01376076 · ClinicalTrials.gov registry record · Phase 1
Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
A Phase 1 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
NCT01376076 is a Phase 1 study that has completed, run by Forest Laboratories. The registered enrollment target is 129 participants.
The verdict
NCT01376076, a Phase 1 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.
Interventions
- DRUG Cariprazine
- DRUG Risperidone/Moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01376076
The ClinicalTrials.gov registry entry for NCT01376076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cariprazine is the first listed.
NCT01376076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01376076 about?
NCT01376076 is a clinical study titled "Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia". This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.
What is the current status of trial NCT01376076?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2011-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01376076?
The interventions under investigation include: Cariprazine (DRUG), Risperidone/Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT01376076?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.